• Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016
Monday Morning
Skip to content
  • Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016

Tag Archives: Ray Takigiku

Unknown Kentucky biotech Bexion tests new glioma med on first patients. Yes, it’s the same cancer Sen. McCain is fighting, and Round B funding is still open.

Steve Walker    August 16, 2018 August 17, 2018    No Comments on Unknown Kentucky biotech Bexion tests new glioma med on first patients. Yes, it’s the same cancer Sen. McCain is fighting, and Round B funding is still open.

The News: Bexion Pharmaceuticals burst out of the shadows of near total obscurity last week as its investigational cancer treatment, BXQ-350, grabbed plenty of mainstream media coverage as a potential game-changer. BXQ-350 is… Read more »

Corporate, Disease, Investment, Pharmaceuticals    American Society for Clinical Oncology, Bexion Pharmaceuticals, Biospace, Bob Rulli, BXQ-350, John McCain, National Cancer Institute, National Institutes of Health, Olivier Rixe, Ray Takigiku, Science Daily, The Cincinnati Enquirer, Xiaoyang Qi

Search The Site

Follow @MonMorningNews

Twitter

Tweets by MonMorningNews
Follow me on Blogarama

Facebook

Search The Site

More MondayMorning

  • Recent Posts
  • Most Commented
  • Most Viewed
  • US stock market has a subdued Thanksgiving week, but a slew of healthcare companies rocketed higher.
  • More Chinese medical companies choosing New York over Shanghai, Hong Kong for IPOs; but not always.
  • Health-sector IPO market cools off for Veterans Day breather; but pre-Thanksgiving deals ready to rock.
  • Health-sector IPO market cools off this week after torrid start to November.
    • Insys trial opens with tale of sales rep giving lap dance to doctor for fentanyl prescriptions. News organizations seize upon...
    • Voyager Therapeutics signs another neurodegenerative disease deal with AbbVie that screams “Buy this small cap now.”
    • Little known Czech biotech’s cell therapy greatly increases survival in ovarian cancer. Sotio’s potential breakthrough and another pipeline cancer candidate...
    • It’s time to reclassify schizophrenia as a neurologic disorder.
    Copyright 2018
    Ribosome by GalussoThemes.com
    Powered by WordPress